The use of cyclizine in patients receiving parenteral nutrition

Authors: Jeremy Nightingale, Uchu Meade, Gavin Leahy and the BIFA committee

April 2019

Cyclizine is a 

*Disclaimer: BAPEN Position Statements/Guidelines have been prepared as guidance only to assist qualified healthcare professionals in the decision making processes surrounding nutritional care. Users of these materials may only do so on the condition that they exercise their own professional knowledge and skills when applying such guidance to specific circumstances. Anyone without the appropriate qualifications must seek the advice of a qualified healthcare professional before taking, or refraining from, any action on the basis of the policies or guidance. BAPEN does not (i) owe a duty of care to users of the policies or guidance who are not qualified healthcare professionals; and (ii) cannot accept liability to anyone using these policies or guidance.*
**Actions/pharmacology (1)**

Cyclizine has both anti-histamine (H1) and anti-cholinergic (anti-muscarinic M1) effects. It is a class 1 drug in the biopharmaceutical classification (high permeability and solubility) with a peak plasma concentration of about 70 ng/ml reached approximately 2 hours after oral ingestion, as measured in healthy adult patients. Its quoted elimination (biological) half-life is 20 hours when given orally (1) and 13 hours when given intravenously (2). Cyclizine is metabolised to its N-demethylated derivative, norcyclizine, which has little anti-histaminic (H1) activity compared to cyclizine. Its therapeutic mechanism of action may primarily be by blocking histamine (H1) and muscarinic cholinergic receptors in the vomiting centre (which includes the chemoreceptor trigger zone). It also has other actions as a central nervous system depressant and a local anaesthetic. Licensed formulations available in the United Kingdom include those that can be administered via the oral, intravenous, intramuscular and subcutaneous routes all at a dose of up to 50 mg three times a day for patients over the age of 18 years (3).

**Undesirable effects relevant to this document (see appendix A for the full list) (3-4)**

Side effects of cyclizine relate mainly to its anti-cholinergic effects and include reduced appetite, constipation, palpitations, postural hypotension and urinary retention. These are particularly relevant as cyclizine is often prescribed to patients with gastrointestinal dysmotility who may have a poor nutritional state, constipation, postural orthostatic tachycardia syndrome (PoTS) and urinary problems. The prescribing of cyclizine in this patient group makes it very hard to distinguish between disease-related and drug related symptoms and signs. Extrapyramidal motor disturbances can occur with chronic use. Agitation is reported especially at high doses and especially in children and the elderly. Liver disease exacerbates its sedative effects as it is metabolised by the liver. Intravenous cyclizine may precipitate at concentrations above 10 mg/mL or in the prolonged presence of sodium chloride 0.9%. It is extremely irritating due to its low pH (3.3-3.7) and can result in vein tracking, erythema, pain, rash, thrombophlebitis and blisters. Central and peripheral vein
damage may lead to a loss of venous access. Concerns have been raised by some home parenteral nutrition (HPN) and intestinal failure (IF) centres that the regular use of cyclizine via a central venous catheter (CVC) can increase the risk of occlusion and traumatic fracture secondary to patients attempting to unblock the CVC. Patients receiving intravenous cyclizine may have more episodes of catheter-related blood stream infections (CRBSIs).

Cyclizine abuse

There have been reports of abuse of cyclizine, either taken orally or intravenously, for its euphoric ("high") or hallucinatory effects (5-9). There has been one reported death in overdose (10) and the committee is aware of at least 2 patients taking cyclizine in an overdose and needing urgent hospital admission (11). The concomitant misuse of cyclizine with large amounts of alcohol is particularly dangerous, since the anti-emetic effect of cyclizine may increase the toxicity of alcohol. Some people using methadone recreationally combine it with cyclizine to enhance the psychoactive effect. The anti-cholinergic effects may induce hallucinations. Addictive behaviour, drug-seeking behaviour and dependence have been documented in some patients needing nutritional support (mainly those with dysmotility) (8).

Potential problems of intravenous cyclizine when used by patients receiving long-term parenteral nutrition (PN)

- Dependence.
- Impaired judgement that may affect the safe completion of the aseptic procedures required for setting up and taking down PN.
- Damage to central and peripheral veins.
- Damage to central venous access devices.
- Increased episodes of catheter-related blood stream infections.

Note: Oral preparations of cyclizine may not be absorbed in patients with intestinal failure.
Alternatives to cyclizine

Although ondansetron or granisetron are more expensive, they may be preferable agents to prescribe as they are equally or more efficacious than cyclizine (12-14). However, constipation is a common adverse effect of all formulations of both ondansetron and granisetron and this should be taken into consideration. In one study of post-operative nausea, cyclizine was less effective than ondansetron or metoclopramide (15). Licensed formulations available in the United Kingdom for ondansetron include those that can be administered via the oral, intravenous, intramuscular and rectal routes and via the oral, intravenous and transdermal route for granisetron. Please check local formularies to see which formulations are available.
Recommendations for Healthcare Professionals

1. Cyclizine should be regarded as a medication that may cause dependence (like opiates).
2. Counsel all patients on the undesirable side effects profile of cyclizine especially the euphoric/addictive effects before prescribing. Healthcare professionals should ask patients if they are experiencing these symptoms after prescribing has commenced.
3. Intravenous cyclizine may be used acutely but should not be used in the long-term.
4. Cyclizine should be used with extreme caution in patients with nausea/vomiting secondary to GI dysmotility.
5. Patients already receiving intravenous cyclizine should be weaned off and other anti-emetic medicines should be considered.
6. Cyclizine impairs judgement so should be used with extreme caution if ever prescribed to patients receiving long-term parenteral nutrition.
7. In patients with recurrent catheter occlusion and or traumatic catheter fracture cyclizine abuse should be considered.
8. The central catheter must be flushed before and after cyclizine and care should also be taken if it is given after any other drug as precipitation may occur (especially if they have a high pH).
9. Any case of dependence should be reported via the MHRA yellow card scheme either using the paper forms found in the back of the British National Formulary or electronically via yellowcard.mhra.gov.uk.
10. Ensure there is only one named prescriber for cyclizine per patient (or per department). The prescriber should be informed at the start of an in-patient episode and any prescriptions should be placed on hold until discharge. On discharge only the smallest amount needed should be supplied until the named prescriber can continue the prescription. Patients should be told that they will not be supplied with additional stock if ampoules are damaged, stolen or lost.
References

1. https://www.medicines.org.uk/emc/product/4318#PHARMACOKINETIC_PROPS


